Development and optimisation of downstream processing for next generation biotherapeutics

全球对廉价生物疗法的需求推动了降低制造成本的需求。重组生产技术的快速发展为血友病、帕金森病和癌症等疾病的治疗提供了新的治疗可能性。然而，由于这些结构的复杂大分子性质，这些下一代蛋白质疗法的纯化极具挑战性。这些新产品需要新的净化工艺来提高生产效率和经济性。这主要是由于目前的色谱纯化技术无法有效地捕获这些大型生物制品，例如基因治疗载体，它们比目前的治疗方法大得多。该项目旨在以现有的合作和可行性数据为基础，开发和商业化一种创新的生物处理技术，使下一代生物治疗药物的生产具有成本效益。

Global demand for cheaper biotherapeutics drives the need for a reduction in manufacturing costs. Rapid advances in recombinant production technologies are offering new therapeutic possibilities in the treatment of illnesses such as haemophilia, Parkinson’s, and cancer. However, purification of these next generation protein therapeutics is extremely challenging due to the complex macromolecular nature of these structures. New purification processes are needed for these novel products to improve manufacturing efficiencies and economics. This is primarily a result of current chromatographic purification technologies being unable to effectively capture these large bioproducts, such as gene therapy vectors, which are much larger than current therapeutics. This project aims to build on existing collaborations and feasibility data to develop and commercialise an innovative bioprocessing technology to enable the cost effective manufacture of a next generation biotherapeutic.